title: Paroxetine in the treatment of melancholia and severe depression.
abstract: Meta-analyses of the worldwide paroxetine database assessed the efficacy of this compound in the treatment of both DSM-III defined melancholia and hospitalised patients with severe depression (HAMD > or = 25). The analysis for melancholia included 178 paroxetine treated patients and 66 patients treated with placebo. Paroxetine was significantly superior to placebo in the treatment of melancholia and a clear dose-response relationship was established. The meta-analysis for severely depressed hospitalised patients included 109 paroxetine treated patients and 107 patients treated with a tricyclic/tetracyclic control. Paroxetine and active controls showed comparable efficacy in the treatment of severely depressed hospitalised patients.
authors: Université de Bordeaux, France.
authors: J
authors: J
authors: Tignol
authors: M J
authors: MJ
authors: Stoker
authors: G C
authors: GC
authors: Dunbar
mesh_terms: D000328:Adult; D003863:Depression / Q000188:drug therapy* / Q000523:psychology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017374:Paroxetine / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
chemical_list: D017374:Paroxetine